Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

@article{Galsky2011TreatmentOP,
  title={Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.},
  author={M. Galsky and N. Hahn and J. Rosenberg and G. Sonpavde and T. Hutson and W. Oh and R. Dreicer and N. Vogelzang and C. Sternberg and D. Bajorin and J. Bellmunt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 17},
  pages={
          2432-8
        }
}
  • M. Galsky, N. Hahn, +8 authors J. Bellmunt
  • Published 2011
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • PURPOSE Cisplatin-based combination chemotherapy is considered standard first-line treatment for patients with metastatic urothelial carcinoma. However, a large proportion of patients with metastatic urothelial carcinoma are considered "unfit" for cisplatin. The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients. PATIENTS AND METHODS In this review, the criteria used to define unfit patients are explored and the results of… CONTINUE READING
    283 Citations

    Paper Mentions

    Interventional Clinical Trial
    Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2… Expand
    ConditionsBladder Carcinoma
    InterventionDrug
    Interventional Clinical Trial
    Phase II Multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with… Expand
    ConditionsMetastatic Urothelial Cancer
    InterventionCombination Product
    [Urothelial cancer: update on systemic treatment options].
    Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
    • 37
    Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer
    • 4
    Evolving Treatment of Advanced Urothelial Cancer.
    • S. Sridhar
    • Medicine
    • Journal of oncology practice
    • 2017
    • 13

    References

    SHOWING 1-10 OF 72 REFERENCES
    Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
    • 44
    Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
    • M. Galsky, G. Chen, +6 authors G. Sonpavde
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2011
    • 56
    • PDF
    A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
    • 163
    Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
    • M. Galsky, G. Chen, +6 authors G. Sonpavde
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2012
    • 89
    Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience
    • 11
    Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
    • 133